Antimicrobial medical devices in preclinical development and clinical use

Biomaterials Associated Infection: Immunological Aspects and Antimicrobial Strategies

Volumn 9781461410317, Issue , 2013, Pages 307-354

  Brooks, Benjamin D ^a   Brooks, Amanda E ^a   Grainger, David W ^a,b  

^a UNIVERSITY OF UTAH   (United States)

^b University of Utah   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMICROBIAL AGENTS; CELL ADHESION; MICROORGANISMS; POLYMERIC IMPLANTS; SURGERY; TARGETED DRUG DELIVERY; TOPOLOGY;

ADVERSE EVENTS; CLINICAL USE; ECONOMIC CONSEQUENCES; HEALTH CONSEQUENCES; IN-VIVO; MEDICAL DEVICE DESIGN; MEDICAL DEVICES; MICROBIAL COLONIZATION; PERFORMANCE; PRECLINICAL DEVELOPMENT;

CONTROLLED DRUG DELIVERY;

EID: 84902453113     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4614-1031-7_13     Document Type: Chapter

References (333)

1. US Food and Drug Administration. Is the product a medical device? 2002; http://www.fda. gov/medicaldevices/deviceregulationandguidance/overview/classifyyourdevice/ucm051512. htm , accessed June, 2012.
2. Simchi A, et al. Recent progress in inorganic and composite coatings with bactericidal capability for orthopaedic applications. Nanomedicine. 2011;7(1):22-39.
3. Chu PK, Liux, editors. Biomaterials fabrication and processing handbook. Boca Raton: CRC Press, Taylor & Francis Group; 2008. p. ix.
4. Zimmerli W, Trampuz A. Implant-associated infections. In Bjarnsholt T, Moser C, Jensen P, Rigshopitalet HS, Hoiby N (Eds): Bio film infections. Springer Science; 2011. pp. 69-89.
5. Medical Devices Industry Outlook-April 2011. 2011 [cited 2012 1/5/2012]. http://www.informationweek.com/news/mobility/business/232301163
6. Popat KC, et al. Titania nanotubes: a novel platform for drug-eluting coatings for medical implants? Small. 2007;3(11):1878-81.
7. Darouiche RO. Treatment of infections associated with surgical implants. N Engl J Med. 2004;350(14):1422-9.
8. von Eiff C, et al. Infections associated with medical devices: pathogenesis, management and prophylaxis. Drugs. 2005;65(2):179-214.
9. Zilberman M, Elsner JJ. Antibiotic-eluting medical devices for various applications. J Control Release. 2008;130:202-15.
10. Hall-Stoodley L, Costerton JW, Stoodley P. Bacterial bio films: from the natural environment to infectious diseases. Nat Rev Microbiol. 2004;2(2):95-108.
11. Gilbert P, Collier PJ, Brown MR. Influence of growth rate on susceptibility to antimicrobial agents: bio films, cell cycle, dormancy, and stringent response. Antimicrob Agents Chemother. 1990;34(10):1865-8.
12. Gristina A. Biomaterial-centered infection: microbial adhesion versus tissue integration. Clin Orthop Relat Res. 2004;(427):4-12.
13. Gristina AG. Biomaterial-centered infection: microbial adhesion versus tissue integration. Science. 1987;237(4822):1588-95.
14. Springer BD, et al. Systemic safety of high-dose antibiotic-loaded cement spacers after resection of an infected total knee arthroplasty. Clin Orthop Relat Res. 2004;427:47-51.
15. Zalavras CG, Patzakis MJ, Holtom P. Local antibiotic therapy in the treatment of open fractures and osteomyelitis. Clin Orthop Relat Res. 2004;427:86-93.
16. Laupland KB, et al. Cost of intensive care unit-acquired bloodstream infections. J Hosp Infect. 2006;63(2):124-32.
17. Bryers JD. Medical bio films. Biotechnol Bioeng. 2008;100(1):1-18.
18. Pollack A. Rising threat of infections unfazed by antibiotics. In: New York Times; 2010.
19. Walker EP. Medicaid to quit paying for preventable events. In: Medpage Today. Washington, DC; 2011.
20. Price JS, et al. Controlled release of antibiotics from coated orthopedic implants. J Biomed Mater Res. 1996;30(3):281-6.
21. Ruszczak Z, Friess W. Collagen as a carrier for on-site delivery of antibacterial drugs. Adv Drug Deliv Rev. 2003;55(12):1679-98.
22. Donlan RM, Costerton JW. Bio films: survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev. 2002;15(2):167-93.
23. Parsek MR, Greenberg EP. Sociomicrobiology: the connections between quorum sensing and bio films. Trends Microbiol. 2005;13(1):27-33.
24. Hetrick EM, Schoen fisch MH. Reducing implant-related infections: active release strategies. Chem Soc Rev. 2006;35(9):780-9.
25. Smith AW. Bio films and antibiotic therapy: is there a role for combating bacterial resistance by the use of novel drug delivery systems? Adv Drug Deliv Rev. 2005;57(10): 1539-50.
26. Francolini I, Donelli G. Prevention and control of bio film-based medical-device-related infections. FEMS Immunol Med Microbiol. 2010;59(3):227-38.
27. Gold HS, Moellering Jr RC. Antimicrobial-drug resistance. N Engl J Med. 1996;335(19):1445-53.
28. Gransden WR. Antibiotic resistance. Nosocomial gram-negative infection. J Med Microbiol. 1997;46(6):436-9.
29. FDA. Premarket Noti fication [510(k)] Submissions for Medical Devices that include antimicrobial agents. FDA; 2007.
30. Davis SC, et al. Microscopic and physiologic evidence for bio film-associated wound colonization in vivo . Wound Repair Regen. 2008;16(1):23-9.
31. Otto M. Staphylococcal Bio films, Vol 322. In: Romeo T, editor. Current Topics in Microbiology and Immunology:Bacterial Bio films. Springer Verlag: Berlin; 2008.
32. Yao Y, et al. Factors characterizing Staphylococcus epidermidis invasiveness determined by comparative genomics. Infect Immun. 2005;73(3):1856-60.
33. Harris LG, Richards RG. Staphylococci and implant surfaces: a review. Injury. 2006;37 Suppl 2:S3-14.
34. An YH, Friedman RJ. Prevention of sepsis in total joint arthroplasty. J Hosp Infect. 1996;33(2):93-108.
35. Friedman RJ. Infection in total joint arthroplasty from distal intravenous lines. A case report. J Arthroplasty. 1988;3(Suppl):S69-71.
36. Broekhuizen CA, et al. Staphylococcus epidermidis is cleared from biomaterial implants but persists in peri-implant tissue in mice despite rifampicin/vancomycin treatment. J Biomed Mater Res A. 2008;85(2):498-505.
37. Al-Fattani MA, Douglas LJ. Penetration of Candida bio films by antifungal agents. Antimicrob Agents Chemother. 2004;48(9):3291-7.
38. Adam B, Baillie GS, Douglas LJ. Mixed species bio films of Candida albicans and Staphylococcus epidermidis . J Med Microbiol. 2002;51(4):344-9.
39. Rohacek M, et al. Bacterial colonization and infection of electrophysiological cardiac devices detected with sonication and swab culture. Circulation. 2010;121(15):1691-7.
40. Trampuz A, Widmer AF. Infections associated with orthopedic implants. Curr Opin Infect Dis. 2006;19(4):349-56.
41. Poelstra KA, et al. Prophylactic treatment of gram-positive and gram-negative abdominal implant infections using locally delivered polyclonal antibodies. J Biomed Mater Res. 2002;60(1):206-15.
42. Elek SD, Conen PE. The virulence of Staphylococcus pyogenes for man; a study of the problems of wound infection. Br J Exp Pathol. 1957;38(6):573-86.
43. Wu P, Grainger DW. Drug/device combinations for local drug therapies and infection prophylaxis. Biomaterials. 2006;27(11):2450-67.
44. Chaloupka K, Malam Y, Seifalian AM. Nanosilver as a new generation of nanoproduct in biomedical applications. Trends Biotechnol. 2010;28(11):580-8.
45. Hartung T. Thoughts on limitations of animal models. Parkinsonism Relat Disord. 2008;14 Suppl 2:S81-3.
46. Levy SB. Active efflux, a common mechanism for biocide and antibiotic resistance. J Appl Microbiol. 2002;92(Suppl):65S-71.
47. Sampath LA, Tambe SM, Modak SM. In vitro and in vivo efficacy of catheters impregnated with antiseptics or antibiotics: evaluation of the risk of bacterial resistance to the antimicrobials in the catheters. Infect Control Hosp Epidemiol. 2001;22(10):640-6.
48. Patti JM, et al. MSCRAMM-mediated adherence of microorganisms to host tissues. Annu Rev Microbiol. 1994;48:585-617.
49. Rodrigues L, et al. Inhibition of microbial adhesion to silicone rubber treated with biosurfactant from Streptococcus thermophilus A. FEMS Immunol Med Microbiol. 2006;46(1): 107-12.
50. Rodrigues L, et al. Biosurfactant from Lactococcus lactis 53 inhibits microbial adhesion on silicone rubber. Appl Microbiol Biotechnol. 2004;66(3):306-11.
51. Rodrigues L, et al. Influence of biosurfactants from probiotic bacteria on formation of bio films on voice prostheses. Appl Environ Microbiol. 2004;70(7):4408-10.
52. Habash M, Reid G. Microbial bio films: their development and signi ficance for medical device-related infections. J Clin Pharmacol. 1999;39(9):887-98.
53. Lee JH, et al. Prosthetic valve endocarditis: clinicopathological correlates in 122 surgical specimens from 116 patients (1985-2004). Cardiovasc Pathol. 2011;20(1):26-35.
54. Sampedro MF, Patel R. Infections associated with long-term prosthetic devices. Infect Dis Clin North Am. 2007;21(3):785-819. x.
55. Darouiche RO. Antimicrobial coating of devices for prevention of infection: principles and protection. Int J Artif Organs. 2007;30(9):820-7.
56. Darouiche RO. Antimicrobial approaches for preventing infections associated with surgical implants. Clin Infect Dis. 2003;36(10):1284-9.
57. Linke D. Bacterial adhesion: chemistry, biology and physics. London: Springer; 2011.
58. Kingshott P, Wei J, Bagge-Ravn D, Gadegaard N, Gram L. Covalent attachment of poly(ethylene glycol) to surfaces, critical for reducing bacterial adhesion. Langmuir. 2003;19:6912-21.
59. Kaper HJ, Busscher HJ, Norde W. Characterization of poly(ethylene oxide) brushes on glass surfaces and adhesion of Staphylococcus epidermidis . J Biomater Sci Polym Ed. 2003; 14(4):313-24.
60. Tebbs SE, Sawyer A, Elliott TS. Influence of surface morphology on in vitro bacterial adherence to central venous catheters. Br J Anaesth. 1994;72(5):587-91.
61. Nagel JA, Dickinson RB, Cooper SL. Bacterial adhesion to polyurethane surfaces in the presence of pre-adsorbed high molecular weight kininogen. J Biomater Sci Polym Ed. 1996;7(9):769-80.
62. Gosheger G, et al. Silver-coated megaendoprostheses in a rabbit model-an analysis of the infection rate and toxicological side effects. Biomaterials. 2004;25(24):5547-56.
63. Lee D, Cohen RE, Rubner MF. Antibacterial properties of Ag nanoparticle loaded multilayers and formation of magnetically directed antibacterial microparticles. Langmuir. 2005;21(21):9651-9.
64. Rojas IA, Slunt JB, Grainger DW. Polyurethane coatings release bioactive antibodies to reduce bacterial adhesion. J Control Release. 2000;63(1-2):175-89.
65. Blaker JJ, Nazhat SN, Boccaccini AR. Development and characterisation of silver-doped bioactive glass-coated sutures for tissue engineering and wound healing applications. Biomaterials. 2004;25(7-8):1319-29.
66. Song WH, Ryu HS, Hong SH. Antibacterial properties of Ag (or Pt)-containing calcium phosphate coatings formed by micro-arc oxidation. J Biomed Mater Res A. 2009;88(1):246-54.
67. Chang TW, Weinstein L. Prevention of herpes keratoconjunctivitis in rabbits by silver sulfadiazine. Antimicrob Agents Chemother. 1975;8(6):677-8.
68. Jung WK, et al. Antibacterial activity and mechanism of action of the silver ion in Staphylococcus aureus and Escherichia coli . Appl Environ Microbiol. 2008;74(7):2171-8.
69. Yang W, et al. Food storage material silver nanoparticles interfere with DNA replication fidelity and bind with DNA. Nanotechnology. 2009;20(8):085102.
70. Feng QL, et al. A mechanistic study of the antibacterial effect of silver ions on Escherichia coli and Staphylococcus aureus . J Biomed Mater Res. 2000;52(4):662-8.
71. Shrivastava, Siddhartha and Bera, Tanmay and Roy, Arnab and Singh, Gajendra and Ramachandrarao, P and Dash, Debabrata. Characterization of enhanced antibacterial effects of novel silver nanoparticles Nanotechnology. 2007; 18(22):5.
72. Rai M, Yadav A, Gade A. Silver nanoparticles as a new generation of antimicrobials. Biotechnol Adv. 2009;27(1):76-83.
73. Samuel U, Guggenbichler JP. Prevention of catheter-related infections: the potential of a new nano-silver impregnated catheter. Int J Antimicrob Agents. 2004;23 Suppl 1:S75-8.
74. Chopra I. The increasing use of silver-based products as antimicrobial agents: a useful development or a cause for concern? J Antimicrob Chemother. 2007;59(4):587-90.
75. Darouiche RO. Device-associated infections: a macroproblem that starts with microadherence. Clin Infect Dis. 2001;33(9):1567-72.
76. Stickler DJ. Biomaterials to prevent nosocomial infections: is silver the gold standard? Curr Opin Infect Dis. 2000;13(4):389-93.
77. Hermans MH. Silver-containing dressings and the need for evidence. Adv Skin Wound Care. 2007;20(3):166-73. quiz 174-5.
78. Zilberman M, et al. Drug-eluting medical implants. Handb Exp Pharmacol. 2010;197:299-341.
79. Kawashita M, et al. Antibacterial silver-containing silica glass prepared by sol-gel method. Biomaterials. 2000;21(4):393-8.
80. Balamurugan A, et al. An in vitro biological and anti-bacterial study on a sol-gel derived silver-incorporated bioglass system. Dent Mater. 2008;24(10):1343-51.
81. Bellantone M, Coleman NJ, Hench LL. Bacteriostatic action of a novel four-component bioactive glass. J Biomed Mater Res. 2000;51(3):484-90.
82. Wu C, et al. Novel sphene coatings on Ti-6Al-4V for orthopedic implants using sol-gel method. Acta Biomater. 2008;4(3):569-76.
83. Kumar R, Howdle S, Munstedt H. Polyamide/silver antimicrobials: effect offiller types on the silver ion release. J Biomed Mater Res B Appl Biomater. 2005;75(2):311-9.
84. Kumar R, Munstedt H. Silver ion release from antimicrobial polyamide/silver composites. Biomaterials. 2005;26(14):2081-8.
85. Choh fiM, et al. Pharmacokinetics, uses, and limitations of vancomycin-loaded bone cement. Int Orthop. 1998;22(3):171-7.
86. Kanellakopoulou K, Giamarellos-Bourboulis EJ. Carrier systems for the local delivery of antibiotics in bone infections. Drugs. 2000;59(6):1223-32.
87. Walenkamp GH, Vree TB, van Rens TJ. Gentamicin-PMMA beads. Pharmacokinetic and nephrotoxicological study. Clin Orthop Relat Res. 1986;205:171-83.
88. Diefenbeck M, Muckley T, Hofmann GO. Prophylaxis and treatment of implant-related infections by local application of antibiotics. Injury. 2006;37 Suppl 2:S95-104.
89. Neut D, et al. The effect of mixing on gentamicin release from polymethylmethacrylate bone cements. Acta Orthop Scand. 2003;74(6):670-6.
90. Neut D, et al. Biomaterial-associated infection of gentamicin-loaded PMMA beads in orthopaedic revision surgery. J Antimicrob Chemother. 2001;47(6):885-91.
91. Fuchs T, et al. The use of gentamicin-coated nails in the tibia: preliminary results of a prospective study. Arch Orthop Trauma Surg. 2011;131(10):1419-25.
92. Schmidmaier G, et al. Prophylaxis and treatment of implant-related infections by antibioticcoated implants: a review. Injury. 2006;37 Suppl 2:S105-12.
93. Brohede U, et al. Multifunctional implant coatings providing possibilities for fast antibiotics loading with subsequent slow release. J Mater Sci Mater Med. 2009;20(9):1859-67.
94. Schierholz JM, et al. Controlled release of antibiotics from biomedical polyurethanes: morphological and structural features. Biomaterials. 1997;18(12):839-44.
95. Kwok CS, Horbett TA, Ratner BD. Design of infection-resistant antibiotic-releasing polymers. II. Controlled release of antibiotics through a plasma-deposited thin film barrier. J Control Release. 1999;62(3):301-11.
96. Kwok CS, et al. Design of infection-resistant antibiotic-releasing polymers: I. Fabrication and formulation. J Control Release. 1999;62(3):289-99.
97. Govender ST, Nathoo N, van Dellen JR. Evaluation of an antibiotic-impregnated shunt system for the treatment of hydrocephalus. J Neurosurg. 2003;99(5):831-9.
98. Joseph TN, Chen AL, Di Cesare PE. Use of antibiotic-impregnated cement in total joint arthroplasty. J Am Acad Orthop Surg. 2003;11(1):38-47.
99. Kress P, Schäfer P, Schwerdtfeger FP. Clinical use of a voice prosthesis with aflap valve containing silver oxide (Blom-Singer Advantage), bio film formation, in-situ lifetime and indication. Laryngorhinootologie. 2006;85(12):893-6.
100. Hancock RE. Mechanisms of action of newer antibiotics for Gram-positive pathogens. Lancet Infect Dis. 2005;5(4):209-18.
101. Tiller JC, et al. Designing surfaces that kill bacteria on contact. Proc Natl Acad Sci USA. 2001;98(11):5981-5.
102. Endo Y, Tani T, Kodama M. Antimicrobial activity of tertiary amine covalently bonded to a polystyrene fiber. Appl Environ Microbiol. 1987;53(9):2050-5.
103. Gottenbos B, et al. In vitro and in vivo antimicrobial activity of covalently coupled quaternary ammonium silane coatings on silicone rubber. Biomaterials. 2002;23(6):1417-23.
104. Flemming RG, et al. Bacterial colonization of functionalized polyurethanes. Biomaterials. 2000;21(3):273-81.
105. Fuchs AD, Tiller JC. Contact-active antimicrobial coatings derived from aqueous suspensions. Angew Chem Int Ed Engl. 2006;45(40):6759-62.
106. Gabriel M, et al. Preparation of LL-37-grafted titanium surfaces with bactericidal activity. Bioconjug Chem. 2006;17(2):548-50.
107. Gelman MA, et al. Biocidal activity of polystyrenes that are cationic by virtue of protonation. Org Lett. 2004;6(4):557-60.
108. Ketonis C, et al. Antibacterial activity of bone allografts: comparison of a new vancomycintethered allograft with allograft loaded with adsorbed vancomycin. Bone. 2011;48(3):631-8.
109. Parvizi J, et al. Frank Stinch field Award. Titanium surface with biologic activity against infection. Clin Orthop Relat Res. 2004;429:33-8.
110. Antoci Jr V, et al. Covalently attached vancomycin provides a nanoscale antibacterial surface. Clin Orthop Relat Res. 2007;461:81-7.
111. Aumsuwan N, Heinhorst S, Urban MW. The effectiveness of antibiotic activity of penicillin attached to expanded poly(tetrafluoroethylene) (ePTFE) surfaces: a quantitative assessment. Biomacromolecules. 2007;8(11):3525-30.
112. Aumsuwan N, et al. Attachment of ampicillin to expanded poly(tetrafluoroethylene): surface reactions leading to inhibition of microbial growth. Biomacromolecules. 2008;9(7):1712-8.
113. Antoci Jr V, et al. The inhibition of Staphylococcus epidermidis bio film formation by vancomycin-modi fied titanium alloy and implications for the treatment of periprosthetic infection. Biomaterials. 2008;29(35):4684-90.
114. Yang J, Welby JL, Meyerhoff ME. Generic nitric oxide (NO) generating surface by immobilizing organoselenium species via layer-by-layer assembly. Langmuir. 2008;24(18):10265-72.
115. Cha W, Meyerhoff ME. Catalytic generation of nitric oxide from S-nitrosothiols using immobilized organoselenium species. Biomaterials. 2007;28(1):19-27.
116. Teller M, et al. Release of gentamicin from bone regenerative materials: an in vitro study. J Biomed Mater Res B Appl Biomater. 2007;81(1):23-9.
117. Gollwitzer H, et al. Antibacterial poly( d , l -lactic acid) coating of medical implants using a biodegradable drug delivery technology. J Antimicrob Chemother. 2003;51(3):585-91.
118. Gollwitzer H, et al. Biomechanical and allergological characteristics of a biodegradable poly( d , l -lactic acid) coating for orthopaedic implants. J Orthop Res. 2005;23(4):802-9.
119. Fitzgerald Jr RH. Microbiologic environment of the conventional operating room. Arch Surg. 1979;114(7):772-5.
120. Steckelberg J, Osmon D. Prosthetic Joint Infection. In: Waldvogel FA, Bisno AL, editors. Infections Associated with Indwelling Medical Devices. American Society of Microbiologists, Washington: D.C.; 2000.
121. Wells CL, Maddaus MA, Simmons RL. Role of the macrophage in the translocation of intestinal bacteria. Arch Surg. 1987;122(1):48-53.
122. Guo W, et al. Enteric bacterial translocation after intraperitoneal implantation of rubber drain pieces. Scand J Gastroenterol. 1993;28(5):393-400.
123. Hill EE, et al. Evolving trends in infective endocarditis. Clin Microbiol Infect. 2006;12(1):5-12.
124. Illingworth BL, et al. In vivo efficacy of silver-coated (Silzone) infection-resistant polyester fabric against a bio film-producing bacteria, Staphylococcus epidermidis . J Heart Valve Dis. 1998;7(5):524-30.
125. Carrel T, et al. De finitive cure of recurrent prosthetic endocarditis using silver-coated St. Jude Medical heart valves: a preliminary case report. J Heart Valve Dis. 1998;7(5):531-3.
126. Grunkemeier GL, Jin R, Starr A. Prosthetic heart valves: objective performance criteria versus randomized clinical trial. Ann Thorac Surg. 2006;82(3):776-80.
127. Jamieson WR, et al. Seven-year results with the St Jude Medical Silzone mechanical prosthesis. J Thorac Cardiovasc Surg. 2009;137(5):1109-15. e2.
128. Ghanbari H, et al. Polymeric heart valves: new materials, emerging hopes. Trends Biotechnol. 2009;27(6):359-67.
129. Atiyeh BS, et al. Effect of silver on burn wound infection control and healing: review of the literature. Burns. 2007;33(2):139-48.
130. Kaufmann BA, et al. Coronary stent infection: a rare but severe complication of percutaneous coronary intervention. Swiss Med Wkly. 2005;135(33-34):483-7.
131. Deiparine MK, et al. Endovascular stent infection. J Vasc Surg. 1996;23(3):529-33.
132. Takahashi H, Letourneur D, Grainger DW. Delivery of large biopharmaceuticals from cardiovascular stents: a review. Biomacromolecules. 2007;8(11):3281-93.
133. Yan Y, et al. Rapamycin can inhibit the development of Chlamydia pneumoniae , which might partly contribute to the prevention of in-stent restenosis. Cardiovasc Drugs Ther. 2010; 24(3):189-95.
134. Spaulding C, et al. Four-year follow-up of TYPHOON (trial to assess the use of the CYPHer sirolimus-eluting coronary stent in acute myocardial infarction treated with BallOON angioplasty). JACC Cardiovasc Interv. 2011;4(1):14-23.
135. Zhang F, Dong L, Ge J. Meta-analysis offive randomized clinical trials comparing sirolimus- versus paclitaxel-eluting stents in patients with diabetes mellitus. Am J Cardiol. 2010;105(1):64-8.
136. Zimarino M, De Caterina R. Actinomycin D-eluting stents do not reduce the risk of restenosis. Commentary. Evid Based Cardiovasc Med. 2005;9(1):41-3.
137. Serruys PW, et al. Actinomycin-eluting stent for coronary revascularization: a randomized feasibility and safety study: the ACTION trial. J Am Coll Cardiol. 2004;44(7):1363-7.
138. Silber S. When are drug-eluting stents effective? A critical analysis of the presently available data. Z Kardiol. 2004;93(9):649-63.
139. Espehaug B, et al. Antibiotic prophylaxis in total hip arthroplasty. Review of 10,905 primary cemented total hip replacements reported to the Norwegian arthroplasty register, 1987 to 1995. J Bone Joint Surg Br. 1997;79(4):590-5.
140. Mahan J, et al. Factors in pin tract infections. Orthopedics. 1991;14(3):305-8.
141. Forster H, et al. Bactericidal activity of antimicrobial coated polyurethane sleeves for external fixation pins. J Orthop Res. 2004;22(3):671-7.
142. von Plocki SC, et al. Biodegradable sleeves for metal implants to prevent implant-associated infection: an experimental in vivo study in sheep. Vet Surg. 2012;41:410-21.
143. Lucke M, et al. Gentamicin coating of metallic implants reduces implant-related osteomyelitis in rats. Bone. 2003;32(5):521-31.
144. Dietz UA, Spor L, Germer CT. Management of mesh-related infections. Chirurg. 2011; 82(3):208-17.
145. Bhende S, et al. Infection potentiation study of synthetic and naturally derived surgical mesh in mice. Surg Infect (Larchmt). 2007;8(3):405-14.
146. Hansen LK, et al. In vivo model of human pathogen infection and demonstration of efficacy by an antimicrobial pouch for pacing devices. Pacing Clin Electrophysiol. 2009;32(7):898-907.
147. Junge K, et al. Gentamicin supplementation of polyvinylidenfluoride mesh materials for infection prophylaxis. Biomaterials. 2005;26(7):787-93.
148. Elliott TS. An update on antimicrobial central venous catheters. J Hosp Infect. 2007;65 Suppl 2:34-8.
149. Drake JM, Kestle JR, Tuli S. CSF shunts 50 years on-past, present and future. Childs Nerv Syst. 2000;16(10-11):800-4.
150. Farber SH, et al. Cost analysis of antibiotic-impregnated catheters in the treatment of hydrocephalus in adult patients. World Neurosurg. 2010;74(4-5):528-31.
151. Choux M, et al. Shunt implantation: reducing the incidence of shunt infection. J Neurosurg. 1992;77(6):875-80.
152. Eymann R, et al. Clinical and economic consequences of antibiotic-impregnated cerebrospinalfluid shunt catheters. J Neurosurg Pediatr. 2008;1(6):444-50.
153. Wong GK, et al. Antibiotics-impregnated ventricular catheter versus systemic antibiotics for prevention of nosocomial CSF and non-CSF infections: a prospective randomised clinical trial. J Neurol Neurosurg Psychiatry. 2010;81(10):1064-7.
154. Parker SL, et al. Comparison of hospital cost and resource use associated with antibioticimpregnated versus standard shunt catheters. Clin Neurosurg. 2011;58:122-5.
155. Pye AD, et al. A review of dental implants and infection. J Hosp Infect. 2009;72(2):104-10.
156. Jokstad A, et al. Quality of dental implants. Int Dent J. 2003;53(6 Suppl 2):409-43.
157. Sones AD. Complications with osseointegrated implants. J Prosthet Dent. 1989;62(5):581-5.
158. Reid G, et al. Microbiota restoration: natural and supplemented recovery of human microbial communities. Nat Rev Microbiol. 2011;9(1):27-38.
159. Walker C, Karpinia K. Rationale for use of antibiotics in periodontics. J Periodontol. 2002;73(10):1188-96.
160. Williams RC, et al. Treatment of periodontitis by local administration of minocycline microspheres: a controlled trial. J Periodontol. 2001;72(11):1535-44.
161. Gabriel MM, Weisbarth RE. Developing antimicrobial surfaces for silicone hydrogels. CIBA Medical; 2009.
162. Szczotka-Flynn LB, Pearlman E, Ghannoum M. Microbial contamination of contact lenses, lens care solutions, and their accessories: a literature review. Eye Contact Lens. 2010; 36(2):116-29.
163. Nilsson SE, Montan PG. The annualized incidence of contact lens induced keratitis in Sweden and its relation to lens type and wear schedule: results of a 3-month prospective study. CLAO J. 1994;20(4):225-30.
164. Cheng KH, et al. Incidence of contact-lens-associated microbial keratitis and its related morbidity. Lancet. 1999;354(9174):181-5.
165. Keay L, et al. Factors affecting the morbidity of contact lens-related microbial keratitis: a population study. Invest Ophthalmol Vis Sci. 2006;47(10):4302-8.
166. Goldstein MH, Kowalski RP, Gordon YJ. Emergingfluoroquinolone resistance in bacterial keratitis: a 5-year review. Ophthalmology. 1999;106(7):1313-8.
167. Zhu H, et al. Fimbrolide-coated antimicrobial lenses: their in vitro and in vivo effects. Optom Vis Sci. 2008;85(5):292-300.
168. Willcox MD. New strategies to prevent Pseudomonas keratitis . Eye Contact Lens. 2007;33(6 Pt 2):401-3. discussion 410-1.
169. Mathews SM, et al. Prevention of bacterial colonization of contact lenses with covalently attached selenium and effects on the rabbit cornea. Cornea. 2006;25(7):806-14.
170. Larkin DF, Kilvington S, Easty DL. Contamination of contact lens storage cases by Acanthamoeba and bacteria. Br J Ophthalmol. 1990;74(3):133-5.
171. Dantam J, Zhu H, Stapleton F. Biocidal efficacy of silver-impregnated contact lens storage cases in vitro . Invest Ophthalmol Vis Sci. 2011;52(1):51-7.
172. Farber BF, et al. A novel antibio film technology for contact lens solutions. Ophthalmology. 1995;102(5):831-6.
173. Collard HR, Saint S, Matthay MA. Prevention of ventilator-associated pneumonia: an evidence-based systematic review. Ann Intern Med. 2003;138(6):494-501.
174. Pruitt B, Jacobs M. Best-practice interventions: how can you prevent ventilator-associated pneumonia? Nursing. 2006;36(2):36-41. quiz 41-2.
175. Ventilator-associated pneumonia (VAP) event. In: CDC, editor; 2011.
176. Tablan OC, Anderson LJ, Besser R, Bridges C, Hajjeh R. Guidelines for preventing healthcare-associated pneumonia, 2003. Recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee. Part 1. Issues on preventing health care associated pneumonia. In: C.f.D. Control, editor. Atlanta, GA; 2003.
177. Kollef MH, et al. Silver-coated endotracheal tubes and incidence of ventilator-associated pneumonia: the NASCENT randomized trial. JAMA. 2008;300(7):805-13.
178. Free RH, et al. Bio film formation on voice prostheses: influence of dairy products in vitro . Acta Otolaryngol. 2000;120(1):92-9.
179. Mahieu HF, et al. Candida vegetations on silicone voice prostheses. Arch Otolaryngol Head Neck Surg. 1986;112(3):321-5.
180. Rodrigues L, et al. Strategies for the prevention of microbial bio film formation on silicone rubber voice prostheses. J Biomed Mater Res B Appl Biomater. 2007;81(2):358-70.
181. De Prijck K, et al. Prevention of Candida albicans bio film formation by covalently bound dimethylaminoethylmethacrylate and polyethylenimine. Mycopathologia. 2010;170(4):213-21.
182. Reddy ST, et al. Micropatterned surfaces for reducing the risk of catheter-associated urinary tract infection: an in vitro study on the effect of sharklet micropatterned surfaces to inhibit bacterial colonization and migration of uropathogenic Escherichia coli . J Endourol. 2011;25(9):1547-52.
183. Hooton TM, et al. Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America Oxford Journals Medicine. Clin Infect Dis. 2009;50(5):625-63.
184. Warren JW. Catheter-associated urinary tract infections. Infect Dis Clin North Am. 1997; 11(3):609-22.
185. Stickler DJ, Jones GL, Russell AD. Control of encrustation and blockage of Foley catheters. Lancet. 2003;361(9367):1435-7.
186. Lawrence EL, Turner IG. Materials for urinary catheters: a review of their history and development in the UK. Med Eng Phys. 2005;27(6):443-53.
187. Horattas MC, et al. Changing concepts in long-term central venous access: catheter selection and cost savings. Am J Infect Control. 2001;29(1):32-40.
188. Tal MG, Ni N. Selecting optimal hemodialysis catheters: material, design, advanced features, and preferences. Tech Vasc Interv Radiol. 2008;11(3):186-91.
189. Sousa C, Henriques M, Oliveira R. Mini-review: antimicrobial central venous catheters-recent advances and strategies. Biofouling. 2011;27(6):609-20.
190. Solomon DD, et al. An in vivo method for the evaluation of catheter thrombogenicity. J Biomed Mater Res. 1987;21(1):43-57.
191. Sherertz RJ, et al. Contribution of vascular catheter material to the pathogenesis of infection: the enhanced risk of silicone in vivo . J Biomed Mater Res. 1995;29(5):635-45.
192. Subbiahdoss G, et al. Microbial bio film growth versus tissue integration: ?the race for the surface? experimentally studied. Acta Biomater. 2009;5(5):1399-404.
193. Roe D, et al. Antimicrobial surface functionalization of plastic catheters by silver nanoparticles. J Antimicrob Chemother. 2008;61(4):869-76.
194. Tambyah PA, Maki DG. The relationship between pyuria and infection in patients with indwelling urinary catheters: a prospective study of 761 patients. Arch Intern Med. 2000;160(5):673-7.
195. Saint S, et al. The efficacy of silver alloy-coated urinary catheters in preventing urinary tract infection: a meta-analysis. Am J Med. 1998;105(3):236-41.
196. Liedberg H. Catheter induced urethral inflammatory reaction and urinary tract infection. An experimental and clinical study. Scand J Urol Nephrol Suppl. 1989;124:1-43.
197. Liedberg H, Lundeberg T. Silver alloy coated catheters reduce catheter-associated bacteriuria. Br J Urol. 1990;65(4):379-81.
198. Rosch W, Lugauer S. Catheter-associated infections in urology: possible use of silver-impregnated catheters and the Erlanger silver catheter. Infection. 1999;27 Suppl 1:S74-7.
199. Maki DG, Tambyah PA. Engineering out the risk for infection with urinary catheters. Emerg Infect Dis. 2001;7(2):342-7.
200. Schierholz JM, et al. The antimicrobial efficacy of a new central venous catheter with longterm broad-spectrum activity. J Antimicrob Chemother. 2000;46(1):45-50.
201. Bullard KM, Dunn DL. Bloodstream and intravascular catheter infections. In: Holzheimer RG, Mannick JA, editors. Surgical treatment: evidence-based and problem-oriented. Munich: Zuckschwerdt; 2001.
202. Widmer AF. Central Venous Catheters. In: Seifert H, Jansen B, Farr BM, editors. Catheter-Related Infections. Marcel Dekker: New York; 1997.
203. McGee DC, Gould MK. Preventing complications of central venous catheterization. N Engl J Med. 2003;348(12):1123-33.
204. Frasca D, Dahyot-Fizelier C, Mimoz O. Prevention of central venous catheter-related infection in the intensive care unit. Crit Care. 2010;14(2):212.
205. Maki DG, et al. Prevention of central venous catheter-related bloodstream infection by use of an antiseptic-impregnated catheter. A randomized, controlled trial. Ann Intern Med. 1997; 127(4):257-66.
206. O?Grady NP, et al. Guidelines for the prevention of intravascular catheter-related infections. Centers for Disease Control and Prevention. MMWR Recomm Rep. 2002;51((RR-10)):1-29.
207. Donlan RM. Bio film elimination on intravascular catheters: important considerations for the infectious disease practitioner. Clin Infect Dis. 2011;52(8):1038-45.
208. Schierholz JM, et al. Antimicrobial substances and effects on sessile bacteria. Zentralbl Bakteriol. 1999;289(2):165-77.
209. Casey AL, et al. Antimicrobial central venous catheters in adults: a systematic review and meta-analysis. Lancet Infect Dis. 2008;8(12):763-76.
210. Boersma RS, et al. Thrombotic and infectious complications of central venous catheters in patients with hematological malignancies. Ann Oncol. 2008;19(3):433-42.
211. Mohammad SF. Enhanced risk of infection with device-associated thrombi. ASAIO J. 2000;46(6):S63-8.
212. Raad II, Hanna HA. Intravascular catheter-related infections: new horizons and recent advances. Arch Intern Med. 2002;162(8):871-8.
213. Stillman RM, et al. Etiology of catheter-associated sepsis. Correlation with thrombogenicity. Arch Surg. 1977;112(12):1497-9.
214. Diskin CJ, et al. Heparin and bio film: is this the risk factor for catheter-related sepsis? Am J Kidney Dis. 2008;52(1):197-8. author reply 198.
215. Baumgartner JN, Cooper SL. Influence of thrombus components in mediating Staphylococcus aureus adhesion to polyurethane surfaces. J Biomed Mater Res. 1998;40(4):660-70.
216. Bos HM, et al. Evidence that bacteria prefer to adhere to thrombus. ASAIO J. 1996; 42(5):M881-4.
217. van Rooden CJ, et al. Infectious complications of central venous catheters increase the risk of catheter-related thrombosis in hematology patients: a prospective study. J Clin Oncol. 2005;23(12):2655-60.
218. Appelgren P, et al. Surface heparinization of central venous catheters reduces microbial colonization in vitro and in vivo : results from a prospective, randomized trial. Crit Care Med. 1996;24(9):1482-9.
219. Tenke P, et al. Bacterial bio film formation on urologic devices and heparin coating as preventive strategy. Int J Antimicrob Agents. 2004;23 Suppl 1:S67-74.
220. Davey ME, O?Toole GA. Microbial bio films: from ecology to molecular genetics. Microbiol Mol Biol Rev. 2000;64(4):847-67.
221. Brunstedt MR, et al. Bacteria/blood/material interactions. I. Injected and preseeded slimeforming Staphylococcus epidermidis inflowing blood with biomaterials. J Biomed Mater Res. 1995;29(4):455-66.
222. Kamal GD, et al. Reduced intravascular catheter infection by antibiotic bonding. A prospective, randomized, controlled trial. JAMA. 1991;265(18):2364-8.
223. Kundu B, et al. Development of porous HAp and beta-TCP scaffolds by starch consolidation with foaming method and drug-chitosan bilayered scaffold based drug delivery system. J Mater Sci Mater Med. 2010;21(11):2955-69.
224. Costerton JW, Stewart PS, Greenberg EP. Bacterial bio films: a common cause of persistent infections. Science. 1999;284(5418):1318-22.
225. Berrington A, Gould FK. Use of antibiotic locks to treat colonized central venous catheters. J Antimicrob Chemother. 2001;48(5):597-603.
226. Mermel LA, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;49(1):1-45.
227. Monson T, Kunin CM. Evaluation of a polymer-coated indwelling catheter in prevention of infection. J Urol. 1974;111(2):220-2.
228. Ahearn DG, et al. Effects of hydrogel/silver coatings on in vitro adhesion to catheters of bacteria associated with urinary tract infections. Curr Microbiol. 2000;41(2):120-5.
229. Thibon P, et al. Randomized multi-centre trial of the effects of a catheter coated with hydrogel and silver salts on the incidence of hospital-acquired urinary tract infections. J Hosp Infect. 2000;45(2):117-24.
230. Bologna RA, et al. Hydrogel/silver ion-coated urinary catheter reduces nosocomial urinary tract infection rates in intensive care unit patients: a multicenter study. Urology. 1999;54(6):982-7.
231. Cormio L, et al. Bacterial adhesion to urethral catheters: role of coating materials and immersion in antibiotic solution. Eur Urol. 2001;40(3):354-8. discussion 359.
232. Pugach JL, et al. Antibiotic hydrogel coated Foley catheters for prevention of urinary tract infection in a rabbit model. J Urol. 1999;162(3 Pt 1):883-7.
233. Boks NP, et al. Bond-strengthening in staphylococcal adhesion to hydrophilic and hydrophobic surfaces using atomic force microscopy. Langmuir. 2008;24(22):12990-4.
234. Boks NP, et al. Residence time dependent desorption of Staphylococcus epidermidis from hydrophobic and hydrophilic substrata. Colloids Surf B Biointerfaces. 2008;67(2):276-8.
235. Boks NP, et al. Mobile and immobile adhesion of staphylococcal strains to hydrophilic and hydrophobic surfaces. J Colloid Interface Sci. 2009;331(1):60-4.
236. Boks NP, et al. Forces involved in bacterial adhesion to hydrophilic and hydrophobic surfaces. Microbiology. 2008;154(Pt 10):3122-33.
237. Banerjee I, Pangule RC, Kane RS. Antifouling coatings: recent developments in the design of surfaces that prevent fouling by proteins, bacteria, and marine organisms. Adv Mater. 2010;23(6):690-718.
238. Chung KK, et al. Impact of engineered surface microtopography on bio film formation of Staphylococcus aureus . Biointerphases. 2007;2(2):89-94.
239. Tebbs SE, Elliott TS. Modi fication of central venous catheter polymers to prevent in vitro microbial colonisation. Eur J Clin Microbiol Infect Dis. 1994;13(2):111-7.
240. Jansen B, et al. In-vitro efficacy of a central venous catheter (?Hydrocath?) loaded with teicoplanin to prevent bacterial colonization. J Hosp Infect. 1992;22(2):93-107.
241. Tamilvanan S, Venkateshan N, Ludwig A. The potential of lipid- and polymer-based drug delivery carriers for eradicating bio film consortia on device-related nosocomial infections. J Control Release. 2008;128(1):2-22.
242. Sampath LA, et al. Infection resistance of surface modi fied catheters with either short-lived or prolonged activity. J Hosp Infect. 1995;30(3):201-10.
243. Romano G, et al. Efficacy of a central venous catheter (Hydrocath) loaded with teicoplanin in preventing subcutaneous staphylococcal infection in the mouse. Zentralbl Bakteriol. 1993;279(3):426-33.
244. Crocker IC, et al. A novel electrical method for the prevention of microbial colonization of intravascular cannulae. J Hosp Infect. 1992;22(1):7-17.
245. Angiotech. Angiotech CVC with anti-microbial surface. 2011 [cited 22 Aug 2011]. http://www.angiotech.com/focus-markets/5fu-cvc/ .
246. Walz JM, et al. Anti-infective external coating of central venous catheters: a randomized, noninferiority trial comparing 5-fluorouracil with chlorhexidine/silver sulfadiazine in preventing catheter colonization. Crit Care Med. 2010;38(11):2095-102.
247. Halton KA, et al. Cost effectiveness of antimicrobial catheters in the intensive care unit: addressing uncertainty in the decision. Crit Care. 2009;13(2):R35.
248. Raad I, et al. Central venous catheters coated with minocycline and rifampin for the prevention of catheter-related colonization and bloodstream infections. A randomized, double-blind trial. The Texas Medical Center Catheter Study Group. Ann Intern Med. 1997; 127(4):267-74.
249. Johnson JR, Delavari P, Azar M. Activities of a nitrofurazone-containing urinary catheter and a silver hydrogel catheter against multidrug-resistant bacteria characteristic of catheter-associated urinary tract infection. Antimicrob Agents Chemother. 1999;43(12):2990-5.
250. Jansen B, et al. In vitro evaluation of the antimicrobial efficacy and biocompatibility of a silver-coated central venous catheter. J Biomater Appl. 1994;9(1):55-70.
251. Shunmugaperumal T. Chapter 11: Polymer-based antimicrobial delivery carriers. In: Shunmugaperumal T, editor. Bio film eradication and prevention: a pharmaceutical approach to medical device infections. Wiley: Hoboken; 2010. pp. 359-417.
252. Stevens KN, et al. The relationship between the antimicrobial effect of catheter coatings containing silver nanoparticles and the coagulation of contacting blood. Biomaterials. 2009;30(22):3682-90.
253. Lansdown A. Silver in healthcare: its antimicrobial efficacy and safety in use. Issues in toxicology. Cambridge: RSC; 2010.
254. Schierholz JM, Beuth J, Pulverer G. Silver coating of medical devices for catheter-associated infections? Am J Med. 1999;107(1):101-2.
255. Schierholz JM, Beuth J, Pulverer G. The quantity and duration of the antimicrobial efficacy of a chlorhexidine and silversulfadiazine impregnated catheter. J Hosp Infect. 1999;42(2): 163-5.
256. Brun-Buisson C, et al. Prevention of intravascular catheter-related infection with newer chlorhexidine-silver sulfadiazine-coated catheters: a randomized controlled trial. Intensive Care Med. 2004;30(5):837-43.
257. Rupp ME, et al. Effect of a second-generation venous catheter impregnated with chlorhexidine and silver sulfadiazine on central catheter-related infections: a randomized, controlled trial. Ann Intern Med. 2005;143(8):570-80.
258. Tattawasart U, et al. Development of resistance to chlorhexidine diacetate and cetylpyridinium chloride in Pseudomonas stutzeri and changes in antibiotic susceptibility. J Hosp Infect. 1999;42(3):219-29.
259. Trautner BW, Darouiche RO. Catheter-associated infections: pathogenesis affects prevention. Arch Intern Med. 2004;164(8):842-50.
260. Terazawa E, et al. Severe anaphylactic reaction due to a chlorhexidine-impregnated central venous catheter. Anesthesiology. 1998;89(5):1296-8.
261. Oda T, et al. Anaphylactic shock induced by an antiseptic-coated central venous [correction of nervous] catheter. Anesthesiology. 1997;87(5):1242-4.
262. Russ BR, Maddern PJ. Anaphylactic reaction to chlorhexidine in urinary catheter lubricant. Anaesth Intensive Care. 1994;22(5):611-2.
263. Burlington B. FDA Public Health Notice: Potential Hypersensitivity Reactions to Chlorhexidine-Impregnated Medica Devices. US Food and Drug Administration: Silver Spring; 1998.
264. Ranucci M, et al. Impact of oligon central venous catheters on catheter colonization and catheter-related bloodstream infection. Crit Care Med. 2003;31(1):52-9.
265. Darouiche RO. Anti-infective efficacy of silver-coated medical prostheses. Clin Infect Dis. 1999;29(6):1371-7. quiz 1378.
266. Veenstra DL, et al. Efficacy of antiseptic-impregnated central venous catheters in preventing catheter-related bloodstream infection: a meta-analysis. JAMA. 1999;281(3):261-7.
267. Krein SL, et al. Use of central venous catheter-related bloodstream infection prevention practices by US hospitals. Mayo Clin Proc. 2007;82(6):672-8.
268. Safdar N. Antimicrobial catheters in the ICU: is the juice worth the squeeze? Crit Care. 2009;13(3):148.
269. Timsit JF, et al. Chlorhexidine-impregnated sponges and less frequent dressing changes for prevention of catheter-related infections in critically ill adults: a randomized controlled trial. JAMA. 2009;301(12):1231-41.
270. Mojibian H, et al. Initial clinical experience with a new heparin-coated chronic hemodialysis catheter. Hemodial Int. 2009;13(3):329-34.
271. Tal MG. Comparison of recirculation percentage of the palindrome catheter and standard hemodialysis catheters in a swine model. J Vasc Interv Radiol. 2005;16(9):1237-40.
272. Kakkos SK, et al. Effectiveness of a new tunneled catheter in preventing catheter malfunction: a comparative study. J Vasc Interv Radiol. 2008;19(7):1018-26.
273. Spector M, et al. Clinical outcome of the Tal Palindrome chronic hemodialysis catheter: single institution experience. J Vasc Interv Radiol. 2008;19(10):1434-8.
274. Mendelson M, Loin-Chen B, Finkelstein-Blond L, Kogan G, Hollinger I. Study of Introcan Safety IV Catheter (IVC) (B.Braun Medical Inc.) for the prevention of percutaneous injuries (PIs) in healthcare workers (HCWs). In: The Society for Healthcare Epidemiology of America; 2003.
275. Cowan MM, et al. Antimicrobial efficacy of a silver-zeolite matrix coating on stainless steel. J Ind Microbiol Biotechnol. 2003;30(2):102-6.
276. Loertzer H, et al. Use of catheters with the AgION antimicrobial system in kidney transplant recipients to reduce infection risk. Transplant Proc. 2006;38(3):707-10.
277. Galeano B, Korff E, Nicholson WL. Inactivation of vegetative cells, but not spores, of Bacillus anthracis , B. cereus , and B. subtilis on stainless steel surfaces coated with an antimicrobial silver-and zinc-containing zeolite formulation. Appl Environ Microbiol. 2003;69(7):4329-31.
278. Chernecky C, Waller J. In vitro comparisons of two antimicrobial intravenous connectors. Clin Nurs Res. 2011;20(1):101-9.
279. Maragakis LL, et al. Increased catheter-related bloodstream infection rates after the introduction of a new mechanical valve intravenous access port. Infect Control Hosp Epidemiol. 2006;27(1):67-70.
280. Ryder M. Bacterial transfer through needleless connectors: a comparison of nine devices. In: SHEA, 2007. Center for Bio film Engineering.
281. Bambauer R, et al. Large bore catheters with surface treatments versus untreated catheters for vascular access in hemodialysis. Artif Organs. 2004;28(7):604-10.
282. Bambauer R, et al. Large bore catheters with surface treatments versus untreated catheters for blood access. J Vasc Access. 2001;2(3):97-105.
283. Kampf G, et al. Microbicidal activity of a new silver-containing polymer, SPI-ARGENT II. Antimicrob Agents Chemother. 1998;42(9):2440-2.
284. Bayston R, et al. Prevention of hydrocephalus shunt catheter colonisation in vitro by impregnation with antimicrobials. J Neurol Neurosurg Psychiatry. 1989;52(5):605-9.
285. Bayston R, Lambert E. Duration of protective activity of cerebrospinalfluid shunt catheters impregnated with antimicrobial agents to prevent bacterial catheter-related infection. J Neurosurg. 1997;87(2):247-51.
286. Zabramski JM, et al. Efficacy of antimicrobial-impregnated external ventricular drain catheters: a prospective, randomized, controlled trial. J Neurosurg. 2003;98(4):725-30.
287. Galal I, El-Hindawy K. Impact of using triclosan-antibacterial sutures on incidence of surgical site infection. Am J Surg. 2011;202(2):133-8.
288. Barie PS. Surgical site infections: epidemiology and prevention. Surg Infect (Larchmt). 2002;3 Suppl 1:S9-21.
289. Leaper DJ, et al. Surgical site infection - a European perspective of incidence and economic burden. Int Wound J. 2004;1(4):247-73.
290. Nichols RL. Preventing surgical site infections: a surgeon's perspective. Emerg Infect Dis. 2001;7(2):220-4.
291. Tajirian AL, Goldberg DJ. A review of sutures and other skin closure materials. J Cosmet Laser Ther. 2010;12(6):296-302.
292. Hochberg J, Meyer KM, Marion MD. Suture choice and other methods of skin closure. Surg Clin North Am. 2009;89(3):627-41.
293. US Food and Drug Administration. Triclosan: what consumers should know;2010.
294. Ford HR, et al. Intraoperative handling and wound healing: controlled clinical trial comparing coated VICRYL plus antibacterial suture (coated polyglactin 910 suture with triclosan) with coated VICRYL suture (coated polyglactin 910 suture). Surg Infect (Larchmt). 2005;6(3):313-21.
295. Stadler S, Fleck T. Triclosan-coated sutures for the reduction of sternal wound infections? A retrospective observational analysis. Interact Cardiovasc Thorac Surg. 2011;13(3):296-9.
296. Fleck T, et al. Triclosan-coated sutures for the reduction of sternal wound infections: economic considerations. Ann Thorac Surg. 2007;84(1):232-6.
297. Deliaert AE, et al. The effect of triclosan-coated sutures in wound healing. A double blind randomised prospective pilot study. J Plast Reconstr Aesthet Surg. 2009;62(6):771-3.
298. Stone J, Gruber TJ, Rozzelle CJ. Healthcare savings associated with reduced infection rates using antimicrobial suture wound closure for cerebrospinalfluid shunt procedures. Pediatr Neurosurg. 2010;46(1):19-24.
299. Rozzelle CJ, Leonardo J, Li V. Antimicrobial suture wound closure for cerebrospinalfluid shunt surgery: a prospective, double-blinded, randomized controlled trial. J Neurosurg Pediatr. 2008;2(2):111-7.
300. Mangram AJ, et al. Guideline for Prevention of Surgical Site Infection, 1999. Centers for Disease Control and Prevention (CDC) Hospital Infection Control Practices Advisory Committee. Am J Infect Control. 1999;27(2):97-132. quiz 133-4; discussion 96.
301. Gomez-Alonso A, et al. Study of the efficacy of Coated VICRYL Plus Antibacterial suture (coated Polyglactin 910 suture with Triclosan) in two animal models of general surgery. J Infect. 2007;54(1):82-8.
302. Storch ML, Rothenburger SJ, Jacinto G. Experimental efficacy study of coated VICRYL plus antibacterial suture in guinea pigs challenged with Staphylococcus aureus . Surg Infect (Larchmt). 2004;5(3):281-8.
303. Barbolt TA. Chemistry and safety of triclosan, and its use as an antimicrobial coating on Coated VICRYL∗ Plus Antibacterial Suture (coated polyglactin 910 suture with triclosan). Surg Infect (Larchmt). 2002;3 Suppl 1:S45-53.
304. Ho C, Spry C. Antibacterial sutures for wound closure after surgery: a review of the clinical effectiveness and long-term adverse effects. Canadian Agency for Drugs and Technologies in Health; 2008.
305. Caperelli L. PolyMedix presents data showing antimicrobial activity of sutures containing PolyCide [05/28/2011 09/19/2011]. http://www.reuters.com/article/2011/06/28/idUS109125+28-Jun-2011+BW20110628 .
306. Chu C-C, Von Fraunhofer JA, Greilser H, editors. Wound closure biomaterials and devices. Boca Raton: CRC; 1997.
307. Moncada S, Higgs EA. Molecular mechanisms and therapeutic strategies related to nitric oxide. FASEB J. 1995;9(13):1319-30.
308. Zhang H, et al. Nitric oxide-releasing fumed silica particles: synthesis, characterization, and biomedical application. J Am Chem Soc. 2003;125(17):5015-24.
309. Rothrock AR, Donkers RL, Schoen fisch MH. Synthesis of nitric oxide-releasing gold nanoparticles. J Am Chem Soc. 2005;127(26):9362-3.
310. Shin JH, Metzger SK, Schoen fisch MH. Synthesis of nitric oxide-releasing silica nanoparticles. J Am Chem Soc. 2007;129(15):4612-9.
311. Hetrick EM, et al. Bactericidal efficacy of nitric oxide-releasing silica nanoparticles. ACS Nano. 2008;2(2):235-46.
312. Friedman AJ, et al. Sustained release nitric oxide releasing nanoparticles: characterization of a novel delivery platform based on nitrite containing hydrogel/glass composites. Nitric Oxide. 2008;19(1):12-20.
313. Frost MC, Reynolds MM, Meyerhoff ME. Polymers incorporating nitric oxide releasing/ generating substances for improved biocompatibility of blood-contacting medical devices. Biomaterials. 2005;26(14):1685-93.
314. Reynolds MM, et al. Tailored synthesis of nitric oxide-releasing polyurethanes using O-protected diazeniumdiolated chain extenders. J Mater Chem. 2010;20(15):3107-14.
315. Fujishima A, Honda K. Electrochemical photolysis of water at a semiconductor electrode. Nature. 1972;238(5358):37-8.
316. Hufschmidt D, et al. Photocatalytic water treatment: fundamental knowledge required for its practical application. Water Sci Technol. 2004;49(4):135-40.
317. Mireles II JR, Toguchi A, Harshey RM. Salmonella enterica serovar typhimurium swarming mutants with altered bio film-forming abilities: surfactin inhibits bio film formation. J Bacteriol. 2001;183(20):5848-54.
318. Rodrigues L, et al. Biosurfactants: potential applications in medicine. J Antimicrob Chemother. 2006;57(4):609-18.
319. Hirota K, et al. Coating of a surface with 2-methacryloyloxyethyl phosphorylcholine (MPC) co-polymer signi ficantly reduces retention of human pathogenic microorganisms. FEMS Microbiol Lett. 2005;248(1):37-45.
320. Cho WK, Kong B, Choi IS. Highly efficient non-biofouling coating of zwitterionic polymers: poly((3-(methacryloylamino)propyl)-dimethyl(3-sulfopropyl)ammonium hydroxide). Langmuir. 2007;23(10):5678-82.
321. Cheng G, et al. Zwitterionic carboxybetaine polymer surfaces and their resistance to longterm bio film formation. Biomaterials. 2009;30:5234-40.
322. Boman HG. Antibacterial peptides: basic facts and emerging concepts. J Intern Med. 2003;254(3):197-215.
323. Thaker HD, et al. Synthetic mimics of antimicrobial peptides from triaryl scaffolds. J Med Chem. 2011;54(7):2241-54.
324. Tew GN, et al. De novo design of antimicrobial polymers, foldamers, and small molecules: from discovery to practical applications. Acc Chem Res. 2010;43(1):30-9.
325. Som A, et al. Synthetic mimics of antimicrobial peptides. Biopolymers. 2008;90(2):83-93.
326. Nagy E, Gie fing C, von Gabain A. Anti-infective antibodies: a novel tool to prevent and treat nosocomial diseases. Expert Rev Anti Infect Ther. 2008;6(1):21-30.
327. Pedron S et al. Combinatorial approach for fabrication of coatings to control bacterial adhesion. J Biomater Sci Polym Ed. 2011; doi:10.1163/092050611X589329.
328. Rosenberg LE, et al. Salicylic acid-based poly(anhydride esters) for control of bio film formation in Salmonella enterica serovar Typhimurium. Lett Appl Microbiol. 2008;46(5):593-9.
329. Tashiro T. Antibacterial and bacterium adsorbing macromolecules. Macromol Mater Eng. 2001;286(2):63-87.
330. Lawson MC, Bowman CN, Anseth KS. Vancomycin derivative photopolymerized to titanium kills S. epidermidis . Clin Orthop Relat Res. 2007;461:96-105.
331. Lawson MC, et al. Inhibition of Staphylococcus epidermidis bio films using polymerizable vancomycin derivatives. Clin Orthop Relat Res. 2010;468(8):2081-91.
332. Lawson MC, et al. Polymerizable vancomycin derivatives for bactericidal biomaterial surface modi fication: structure-function evaluation. Biomacromolecules. 2009;10(8):2221-34.
333. Donlan RM. Biofilms and device-associated infections. Emerg Infect Dis. 2001;7(2):277-81.